Kim SY, et al. • Steroid-induced Diabetes 4. Kim HB, Han KH, Chung JY, Lee BW, Kweon SH, Kim BI, Lee M, Lee SJ, Lee HS, Imm CW. Clinical study on coronary risk factors in NIDDM. Korean J Intern Med 1992; 43: 770-5. 5. The Diabetes Control and Complications Trial Research Group. The ef - fect of intensive treatment of diabetes on the development and progres- sion of long-term complications in insulin-dependent diabetes melli- tus. N Engl J Med 1993; 329: 977-86. 6. Tryfon S, Papanas N. Corticosteroid-induced diabetes in patients with chronic obstructive pulmonary disease. Clin Pulm Med 2008; 15: 127-31. 7. Montori VM, Basu A, Erwin PJ, Velosa JA, Gabriel SE, Kudva YC. Post- transplantation diabetes: a systematic review of the literature. Diabetes Care 2002; 25: 583-92. 8. Panthakalam S, Bhatnagar D, Klimiuk P. The prevalence and manage - ment of hyperglycaemia in patients with rheumatoid arthritis on corti- costeroid therapy. Scott Med J 2004; 49: 139-41. 9. Smyllie HC, Connolly CK. Incidence of serious complications of cortico- steroid therapy in respiratory disease. A retrospective survey of patients in the Brompton hospital. Thorax 1968; 23: 571-81. 10. Uzu T, Harada T, Sakaguchi M, Kanasaki M, Isshiki K, Araki S, Sugiomo- to T, Koya D, Haneda M, Kashiwagi A, Yamauchi A. Glucocorticoid-in- duced diabetes mellitus: prevalence and risk factors in primary renal diseases. Nephron Clin Pract 2007; 105: c54-7. 11. Iwamoto T, Kagawa Y, Naito Y, Kuzuhara S, Kojima M. Steroid-induced diabetes mellitus and related risk factors in patients with neurologic diseases. Pharmacotherapy 2004; 24: 508-14. 12. Raúl Ariza-Andraca C, Barile-Fabris LA, Frati-Munari AC, Baltazár- Montufar P. Risk factors for steroid diabetes in rheumatic patients. Arch Med Res 1998; 29: 259-62. 13. Arner P, Gunnarsson R, Blomdahl S, Groth CG. Some characteristics of steroid diabetes: a study in renal-transplant recipients receiving high- dose corticosteroid therapy. Diabetes Care 1983; 6: 23-5. 14. Iozzo P, Beck-Nielsen H, Laakso M, Smith U, Yki-Järvinen H, Ferrannini E. Independent influence of age on basal insulin secretion in nondiabetic humans. European Group for the Study of Insulin Resistance. J Clin En- docrinol Metab 1999; 84: 863-8. 15. Kim SG, Yang SW, Choi SI, Park SH, Lee KR, Park JH, Jang AS, Seo JP, Lee S, Nam HS, Sun MH, Shin MG, Chung DJ, Chung MY. Prevalence of diabetes mellitus in the elderly of Namwon county, South Korea. Kore- an J Med 2001; 60: 555-66. 16. Korean National Health and Nutrition Examination Survey. 2008. Avail- able at http://knhanes.cdc.go.kr [accessed on 13 Jul 2010]. 17. Thearle M, Brillantes AM.Unique characteristics of the geriatric diabetic population and the role for therapeutic strategies that enhance glucagon- like peptide-1 activity. Curr Opin Clin Nutr Metab Care 2005; 8: 9-16. 18. Chang AM, Halter JB. Aging and insulin secretion. Am J Physiol Endo- crinol Metab 2003; 284: E7-12. 19 Hoogwerf B, Danese RD. Drug selection and the management of corti- costeroid-related diabetes mellitus. Rheum Dis Clin North Am 1999; 25: 489-505. AUTHOR SUMMARY Incidence and Risk Factors of Steroid-induced Diabetes in Patients with Respiratory Disease Seo Yun Kim, Chul-Gyu Yoo, Chun Taeg Lee, Hee Soon Chung, Young Whan Kim, Sung Koo Han, Young-Soo Shim, and Jae-Joon Yim We investigated the incidence and risk factors of steroid-induced diabetes mellitus (S-DM) in patients treated with glucocorticoid for respiratory diseases. A retrospective study examined patients with respiratory diseases treated with a prednisolone-equivalent glucocorticoid dose exceeding 20 mg/day for at least 4 weeks. S-DM was defined as a fasting glucose concentration exceeding 126 mg/dL or a random glucose concentration exceeding 200 mg/dL at least twice after beginning steroid treatment. A total of 231 patients met the inclusion criteria. The median cumulative prednisolone-equivalent glucocorticoid dose was 4,965 mg, and the median duration of steroid treatment was 193 days. S-DM was diagnosed in 34 (14.7%) of 231 patients. Older age was identified as a risk factor for S-DM. In conclusion, clinicians should be aware of the possibility of S-DM for patients with respiratory diseases, especially among patients. DOI: 10.3346/jkms.2011.26.2.264 http://jkms.org 267